Key Highlights
- HIMS shares climbed 7% following the integration of Eli Lilly’s Zepbound and additional GLP-1 medications
- Platform clinicians gained prescription access to Zepbound vials, KwikPen, and Foundayo through LillyDirect pharmacy
- The company previously secured a partnership with Novo Nordisk for Wegovy injections and oral formulations
- J.P. Morgan launched coverage with an “Overweight” designation and $35 price objective
- Analysts forecast revenue expansion from $2.3B in 2025 to beyond $3.2B by 2027, alongside $414M in EBITDA
Hims & Hers Health surged 7% Thursday following the telehealth provider’s announcement that it would integrate weight management therapies from Eli Lilly into its service offerings.
Hims & Hers Health, Inc., HIMS
Healthcare providers operating through the Hims & Hers platform gained the ability to prescribe Zepbound vials, KwikPen devices, and Foundayo. Patients can fulfill these prescriptions via the LillyDirect pharmacy, with self-pay pricing structures made available to the company’s customer base.
The expansion provides licensed medical professionals on the platform with streamlined pathways to connect patients with FDA-cleared GLP-1 therapies.
This arrangement builds upon a collaboration unveiled in the previous month with Novo Nordisk. That agreement granted Hims & Hers customers access to Wegovy injection products and oral treatment options.
The two partnerships represent a strategic repositioning of the company’s domestic weight management approach. Company representatives attribute the evolution to rising consumer demand and evolving marketplace conditions surrounding GLP-1 medications.
The weight management program encompasses round-the-clock care team availability, customized nutrition guidance, clinical monitoring appointments, and community engagement through its Weight Loss support network.
Hims & Hers emphasizes its commitment to providing diverse treatment pathways customized to each patient’s medical background and wellness objectives.
J.P. Morgan Launches Coverage With Positive Stance
The stock received additional momentum Friday when J.P. Morgan launched coverage with an “Overweight” designation and established a $35 price objective.
Bank analysts identified the Novo Nordisk collaboration as a pivotal development for the weight-loss division, noting it diminishes regulatory exposure associated with compounded GLP-1 products while expanding access to branded pharmaceutical treatments.
J.P. Morgan calculates HIMS is positioned to surpass 100,000 monthly Wegovy prescriptions, representing an annualized revenue trajectory of approximately $350–$400 million from that single product line.
The investment bank additionally highlighted peptide-based treatment options as a significant long-range growth catalyst. With federal regulators evaluating clearance for widespread compounding of multiple peptides, Hims & Hers’ proprietary manufacturing capabilities could position it advantageously.
Financial Projections and Business Trajectory
J.P. Morgan anticipates revenue climbing from $2.3 billion in 2025 to surpass $3.2 billion by 2027, with EBITDA reaching $414 million. Company leadership has established targets for sustained annual revenue growth exceeding 20% through 2030.
Revenue acceleration is anticipated during the latter half of 2026 as emerging specialty areas mature and branded product offerings enhance customer profitability metrics.
Challenges persist, however. The stock maintains one of the highest short interest levels within its sector. Shareholder concerns encompass decelerating growth rates, escalating customer acquisition expenses, and competitive pressure from Amazon and telehealth competitor Ro.
J.P. Morgan recognized these headwinds while asserting the current market valuation underrepresents the company’s expansion trajectory.
HIMS provides services to roughly 2.5 million subscribers spanning weight management, sexual wellness, and dermatological care. Its end-to-end integrated structure—encompassing medical practitioners, pharmacy operations, and production facilities—was emphasized by J.P. Morgan as a fundamental competitive differentiator.
At the time of publication, Novo Nordisk (NVO) traded up 5.53% while Eli Lilly (LLY) declined 2.84% during the session.
